[Evaluation of adverse effects including neurotoxicity of combination chemotherapy with paclitaxel and carboplatin].
The adverse effects of combination chemotherapy with paclitaxel and carboplatin, including neurotoxicity, arthralgia and muscle pain, were evaluated in 21 patients (30 courses) using questionnaires of the Gynecologic Oncology Chemotherapy Joint Research Group. The scores of pain and numbness peaked from the third to fourth day of treatment. Although the pain score improved subsequently, the numbness score persisted at a high level. Compared to the first and second courses, the peak pain score was higher and persisted for a longer duration in the fifth and sixth courses. Using the questionnaires, we were able to recognize a high incidence of numbness and pain in patients on combination chemotherapy with paclitaxel and carboplatin, and identify the degree and temporal changes of the adverse effects. Our results suggest that the questionnaires used in this study are clinically useful for evaluating the degree and clinical course of pain and numbness in anticancer chemotherapy.
Tate
S
S
Dept. of Obstetrics and Gynecology, Chiba Municipal Hospital.
Iwasaki
H
H
Matsui
H
H
Hirai
Y
Y
Sekiya
S
S
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000009:adverse effects*; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006987:Hypesthesia / Q000139:chemically induced*; D009325:Nausea / Q000139:chemically induced; D009437:Neuralgia / Q000139:chemically induced*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D010147:Pain Measurement; D012678:Sensation Disorders / Q000139:chemically induced; D011795:Surveys and Questionnaires
D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D016190:Carboplatin; D017239:Paclitaxel